Eli Lilly (LLY) said early Thursday its experimental obesity drug delivered strong weight loss in a late-stage trial. In premarket trade, Eli Lilly stock rose slightly, eyeing a key level. Patients on the highest dose lost an average of 23.7% of body weight at 68 weeks, including the 18% that discontinued treatment. The patients also reported a 62% reduction in…
